Morphology of bone metastasis

European Journal of Cancer

Volumn 34, Issue 2, 1998, Pages 230-239

  Hiraga, T ^a   Tanaka, S ^b   Ikegame, M ^a   Koizumi, M ^c   Iguchi, H ^d   Nakajima, T ^a   Ozawa, H ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; INCADRONIC ACID;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BONE METASTASIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; TUMOR LOCALIZATION;

EID: 0032512919     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10131-9     Document Type: Article

References (49)

1. 1. Yamaguchi T, Tamai K, Yamato M, Honma K, Ueda Y, Saotome K. Intertrabecular pattern of tumor metastatic to bone. Cancer 1996, 78(7), 1388-1394.
2. 2. Moriwaki S. Histopathology of metastatic bone tumors. Jpn J Cancer Chemother 1987, 14, 1680-1687. (in Japanese)
3. 3. Mundy GR, Yoneda T. Facilitation and suppression of bone metastasis. Clin Orthop Relat Res 1995, 312, 34-44.
4. 4. Nemoto R. New bone formation and cancer implants; relationship to tumour proliferative activity. Br J Cancer 1991, 63, 348-350.
5. 5. Hulth A, Olerud S. The reaction of bone to experimental cancer. Acta Orthoped Scandinav 1965, 36, 230-240.
6. 6. Krempien B, Wingen F, Eichmann T, Muller M, Schmahl D. Protective effects of a prophylactic treatment with the bisphosphonate 3-amino-1-hydroxypropane-1, 1-bisphosphonic acid on the development of tumor osteopathies in the rat: experimental studies with the Walker carcinosarcoma 256. Oncology 1988, 45, 41-46.
7. 7. O'Grady RL, Cameron DA. Osteoclasts and the resorption of bone by transplanted mammary carcinoma in rats. Br J Cancer 1985, 51, 767-774.
8. 8. Nemoto R, Kanoh S, Koiso K, Shigenori S, Kabashima T, Haebara H. Local bone resorption induced by serially transplantable human renal cell carcinoma in nude mice. Urol Int 1987, 42, 326-329.
9. 9. Powles TJ, Clark SA, Easty DM, Easty GC, Neville AM. The inhibition by aspirin and indomethacin of osteolytic tumour deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer. Br J Cancer 1973, 28, 316-321.
10. 10. Jung A, Bornand J, Mermillod B, Edouard C, Meunier PJ. Inhibition by diphosphonate of bone resorption induced by the Walker tumor of the rat. Cancer Res 1984, 44, 3007-3011.
11. 11. Iwakawa M, Ando K, Ohkawa H, Koike S, Chen YJ. A murine model for bone marrow metastasis established by an i.v. injection of C-1300 neuroblastoma in A/J mice. Clin Exp Metastasis 1994, 12, 231-237.
12. 12. Shevrin DH, Kukreja SC, Ghosh L, Lad TE. Development of skeletal metastasis by human prostate cancer in athymic nude mice. Clin Exp Metastasis 1988, 6, 401-409.
13. 13. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988, 48, 6876-6881.
14. 14. Nakai M, Mundy GR, Williams PJ, Boyce B, Yoneda T. A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mouse. Cancer Res 1992, 52, 5395-5399.
15. 15. Hall DG, Stoica G. Effect of the bisphosphonate risedronate on bone metastases in rat mammary adenocarcinoma model system. J Bone Miner Res 1994, 9, 221-230.
16. 16. Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Research 1995, 55, 3551-3557.
17. 17. Izbicka E, Dunstan C, Esparza J, Jacobs C, Sabatini M, Mundy GR. Human amniotic tumor that induces new bone formation in vivo produces a growth-regulatory activity in vitro for osteoblasts identified as an extended form of basic fibroblast growth factor. Cancer Res 1996, 56, 633-636.
18. 18. Hiraga T, Nakajima T, Ozawa H. Bone resorption by a metastatic human melanoma cell line. Bone 1995, 16, 349-356.
19. 19. Taylor LM, Tertinegg I, Okuda A, Heersche JNM. Expression of calcitonin receptors during osteoclast differentiation in mouse metatarsals. J Bone Miner Res 1989, 4, 751-758.
20. 20. Hattersley G, Chambers TJ. Calcitonin receptors as markers for osteoclastic differentiation: correlation between generation of bone-resorptive cells and cells that express calcitonin receptors in mouse bone marrow cultures. Endocrinol 1989, 125, 1606-1612.
21. 21. Udagawa N, Takahashi N, Akatsu T, et al. The bone marrow-derived stromal cell line MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in co-cultures with mouse spleen cells. Endocrinol 1989, 125, 1805-1813.
22. 22. Caligaris-Cappis F, Bergui L, Gregoretti MG, et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991, 77, 2688-2693.
23. 23. Globus RK, Plouet J, Gospodarowicz D. Cultured bovine bone cells synthesize basic fibroblast growth factor and store it in their extracellular matrix. Endocrinol 1989, 124, 1539-1547.
24. 24. Klagsbrun M. The affinity of fibroblast growth factor (FGFs) for heparin; FGF-heparin sulfate interaction in cells and extracellular matrix. Curr Opinion Cell Biol 1990, 2, 857-863.
25. 25. Gospodarowicz D, Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 1986, 128, 475-484.
26. 26. Saksela O, Moscatelli D, Sommer A, Rifkin DB. Endothelial cell-derived heparan sulfate binds basic growth factor and protects it from proteolytic degradation. J Cell Biol 1988, 107, 743-751.
27. 27. Fuller K, Gallagher AC, Chambers TJ. Osteoclast resorption-stimulating activity is associated with the osteoclast cell surface and/or the extracellular matrix. Biochem Biophys Res Commun 1991, 181, 67-73.
28. 28. Iguchi H, Tanaka S, Ozawa Y, et al. An experimental model of bone metastasis by human lung cancer cells: the role of parathyroid hormone-related protein in bone metastasis. Cancer Res 1996, 56, 4040-4043.
29. 29. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996, 98, 1544-1549.
30. 30. Shea JF, Yeager VL, Taylor JJ. Bone resorption by osteocytes. Proc Soc Exp BiolMed 1968, 129, 41-43.
31. 31. Belanger LF. Ostecytic osteolysis. Calcif Tissue Res 1969, 4, 1-12.
32. 32. Mundy GR, Altman AJ, Gondek MD, Bandelin JG. Direct resorption of bone by human monocytes. Science 1977, 196, 1109-1111.
33. 33. Kahn AJ, Steward CC, Teitelbaum SL. Contact-mediated bone resorption by human monocytes in vitro. Science 1978, 199, 988-990.
34. 34. Koeffler HP, Mundy GR, Golde DW, Cline MJ. Production of bone resorbing activity in poorly differentiated monocytic malignancy. Cancer 1978, 41, 2438-2443.
35. 35. Athanasou NA, Quinn JMW. Human tumour-associated macrophages are capable of bone resorption. Br J Cancer 1992, 65, 523-526.
36. 36. Quinn JMW, Matsumura Y, Tarin D, McGee JO, Athanasou NA. Cellular and hormonal mechanisms associated with malignant bone resorption. Lab Invest 1994, 71, 453-455.
37. 37. Eilon G, Mundy GR. Direct resorption of bone by human breast cancer cells in vitro. Nature 1978, 276, 726-728.
38. 38. Sweatman OH, Khokha R, Kruger A, et al. Evidence for tumor-mediated osteolysis in experimental human bone metastasis. Proc Am Assoc Cancer Res 1996, 37, 88 (abstract).
39. 39. Galasko CSB. Mechanisms of bone destruction in the development of skeletal metastasis. Nature 1976, 263, 507-508.
40. 40. Orr FW, Sanchez Sweatman OH, Kostenuik P, Singh G. Tumor-bone interactions in skeletal metastasis. Clin Orthop Relat Res 1995, 312, 19-33.
41. 41. Van De Wijngaert FP, Burger EH. Demonstration of tartrate-resistant acid phosphatase in undecalcified, glycolmethacrylate-embedded mouse bone: a possible marker for (pre)osteoclast identification. J Histochem Cytochem 1986, 34, 1317-1323.
42. 42. Rodan GA, Fleisch HA. Bisphosphonates: mechanism of action. J Clin Invest 1996, 97, 2692-2696.
43. +-ATPase. J Bone Miner Res 1996, 11, 1498-1507.
44. 44. Zimolo Z, Wesolowski G, Rodan GA. Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin. J Clin Invest 1995, 96, 2277-2283.
45. 45. Endo N, Rutledge SJ, Opas EE, Vogel R, Rodan GA, Schmidt A. Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res 1996, 11, 535-543.
46. 46. Schmidt A, Rutledge SJ, Endo N, et al. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci U.S.A. 1996, 93, 3068-3073.
47. 47. Hiraga T, Tanaka S, Yamamoto M, Nakajima T, Ozawa H. Inhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumor. Bone 1996, 18, 1-8.
48. 48. Tanaka S, Hiraga T, Ozawa Y, et al. YM175 inhibits tumor-induced osteolysis in nude mice with bone metastases. J Bone Miner Res 1995, 10, S194 (abstract).
49. 49. Hiraga T, Takada M, Nakajima T, Ozawa H. Effects of bisphosphonate (pamidronate) on bone resorption resulting from metastases of a human squamous cell carcinoma. Report of an autopsy case and evaluation of bone resorbing activity by animal experimental model. J Oral Maxillofac Surg 1996, 54, 1327-1333.